Scott Ericksen Sells 500 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 500 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Down 1.1%

Illumina stock opened at $162.55 on Wednesday. The company has a 50-day simple moving average of $134.48 and a 200-day simple moving average of $132.39. The firm has a market capitalization of $24.59 billion, a P/E ratio of 29.55, a P/E/G ratio of 2.72 and a beta of 1.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a one year low of $78.79 and a one year high of $165.97.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, signaling confidence in further upside for the genomics leader. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are being optimized on Illumina software, a small but constructive development that could reinforce Illumina’s ecosystem in cancer research and data analysis. Business Wire article
• Neutral Sentiment: Recent news about genomics and synthetic biology stocks being in the spotlight highlights ongoing investor interest in the sector, though the coverage did not specifically point to Illumina as a named leader in those articles. Yahoo Finance article
• Neutral Sentiment: Illumina reported strong prior-quarter results, beating EPS and revenue estimates and maintaining FY2026 guidance, which continues to underpin the stock’s fundamental case. MarketBeat article
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, and CAO Scott D. Ericksen also sold stock. While the sales were disclosed and one was under a 10b5-1 plan, the size and frequency of insider selling can weigh on investor sentiment. SEC filing

Analyst Upgrades and Downgrades

Several research firms recently commented on ILMN. Barclays raised their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Guggenheim raised their price target on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday. UBS Group restated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Citigroup upped their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $138.38.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. JPMorgan Chase & Co. grew its stake in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after purchasing an additional 124,246 shares during the last quarter. Elo Mutual Pension Insurance Co acquired a new stake in Illumina during the third quarter valued at approximately $2,319,000. Caprock Group LLC bought a new stake in Illumina during the third quarter worth approximately $1,479,000. Nordea Investment Management AB boosted its holdings in Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after buying an additional 911,843 shares in the last quarter. Finally, Capital World Investors grew its position in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after buying an additional 3,331,542 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.